Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 668-672, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-922239
ABSTRACT
Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear. This article combines the recent research results of ICIs to summarize the mechanism and clinical manifestations of ICIs-related myocarditis, so as to improve clinicians' understanding of the adverse reactions.
.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pesquisa Biomédica
/
Cardiotoxicidade
/
Inibidores de Checkpoint Imunológico
/
Imunoterapia
/
Miocardite
/
Neoplasias
Limite:
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS